Till-Manuel Saur is a Venture Capital and M&A Partner in our Berlin Office. He focusses on transactions involving start-ups, scale-ups and emerging growth companies. 

Till advises venture capital funds, corporates, target companies and founders on transactions during the entire lifecycle of venture-capital-backed companies. He specializes on advising on equity, convertible loan and (venture) debt financing rounds as well as exit transactions.  

His experience of advising on several hundred transactions gives Till a deep understanding of current market trends and the challenges that start-ups face during growth and expansion phase. 

Till joined Osborne Clarke in 2014 after training with international law firms in London and New York City. 

Till is recognised by the legal directory JUVE as “often recommended” for Venture Capital Transactions and listed in Best Lawyers for Venture Capital Law.

Helping you succeed in tomorrow's world

In a digitized world, young businesses need optimistic risk takers to partner with them on their entrepreneurial journey. With a keen interest on disrupting business models, I help the challengers of today becoming the market leaders of tomorrow. 

Together with the German Standards Setting Institute, I help to provide the German start-up ecosystem with easily accessible model contracts for early stage venture capital financings. 

CODE University

Osborne Clarke has advised the start-up university CODE University of Applied Sciences on the establishment of the CODE Trust, read more.

naturalX Health Ventures

Osborne Clarke has advised naturalX Health Ventures, the venture capital arm of Schwabe Group, on its investment in a Series A funding round in nutritional supplement start-up mybacs, read more.

QuantumDiamonds

Osborne Clarke has advised QuantumDiamonds GmbH, a Munich-based start-up for quantum sensor technology, on its successful seed financing round, read more.

Prematch

Osborne Clarke has once again advised Prematch, the Cologne-based social platform for amateur football, on a successfully completed financing round, read more.

Nosh.bio

Osborne Clarke advises Nosh.bio on seed funding round, read more

Brandenburg Kapital

Osborne Clarke advises Brandenburg Kapital on investment in DearEmployee, read more

Klima Energy Transition Fund

Osborne Clarke advises Klima Energy Transition Fund on Series B financing round of digital energy trading platform Enmacc, read more

Keen Venture Partners

Osborne Clarke advises Keen Venture Partners on EUR 25 million investment in Lendis, read more

Softr

Osborne Clarke advises Softr in USD 13.5 million Series A financing round, read more

JUNIQE

Osborne Clarke berät Gesellschafter von JUNIQE bei Verkauf der Anteile, lesen Sie hier mehr

Highland Europe

Osborne Clarke advises Highland Europe on investment in SoSafe, read more

Stenon

Osborne Clarke advises Stenon in USD 20 million Series A financing, read more

Blickfeld

Osborne Clarke advises Blickfeld on USD 31 million Series A funding, read more

N26

Osborne Clarke advises N26 in billion-dollar funding round with top investors.

Bluu Biosciences

Osborne Clarke advises Bluu Biosciences in EUR 7 Mio financing round, read more

Highland Europe

Osborne Clarke advises Highland Europe on Camunda financing round. 

Hepster

Osborne Clarke advises Hepster on USD 10 Million Series A funding round, read more

Adjust and Applovin

Osborne Clarke advises investors on the merger of Adjust with Applovin, read more

Softr

Osborne Clarke advises Softr on USD 2.2m seed round, read more

Emmy

Osborne Clarke advises Emmy on Series C financing round, read more

Insights